Why the study?
Coxsackievirus A4 has caused global outbreak epidemics of severe herpangina, but no effective vaccines or drugs are currently available.
A novel juvenile mouse model for coxsackievirus A4 was successfully established and validated as a tool for evaluating the efficacy of antiviral therapies.
Should not yet change practice; leaves open whether CVA4 antivirals will translate from this new juvenile mouse model.
Coxsackievirus A4 (CVA4) as a pathogen causing severe herpangina has become global outbreak epidemics during the past 5 years. However, there is currently no effective vaccines and drugs available. Here, one mouse-adapted CVA4 virus (YZ08) was cultivated by repeatedly cross-passaging between human RD cells and 11-day-old juvenile mice. Our results revealed the YZ08 virus was highly lethal to 13-day-old juvenile mice. Virus titer assay indicated that the YZ08 virus effectively replicated in juvenile mice. This model was successfully used to evaluate the therapeutic efficacy of herb medicine, anti-CVA4 rabbit sera, and antiviral drugs. Our results indicated that all tested reagents effectively provided protection for CVA4 virus infection by prolonging survival time, promoting survival, and preventing weight loss. Collectively, we successfully established a juvenile mouse model of CVA4 virus, which was a powerful tool for investigating the pathogenesis of CVA4 or evaluating the efficacy of antiviral reagents or vaccines.
No takes yet. Share an insight, caveat, or question.
Su et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: